Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8785031 | Advances in Radiation Oncology | 2017 | 9 Pages |
Abstract
IMPT dose escalation to CTV2 to 63 GyRBE was achieved without acute dose limiting toxicities. The phase 2 study of IMPT will accrue patients to that dose. Parallel intensity modulated radiation therapy phase 1 arm is currently accruing at the initial dose level. Ureters that undergo a high dose radiation and/or surgery are at risk for late hydro-ureter. Future studies will constrain retained ureters to 50.4 GyRBE to avoid ureteral stricture.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Thomas F. MD, Yen-Lin MD, Elizabeth H. MD MPH, Dian MD PhD, Judith CMD, Shea B. BA, Beow Y. ScD, Stephen M. MD, Karen MD, G. Petur MD, Edwin MD PhD, John T. MD, Sam S. MD,